The clinical effectiveness of optical spectroscopy for the in vivo diagnosis of cervical intraepithelial neoplasia:: Where are we?

被引:33
作者
Cardenas-Turanzas, Marylou
Freeberg, J. Adrian
Benedet, J. L.
Atkinson, E. Neely
Cox, Dennis D.
Richards-Kortum, Rebecca
MacAulay, Calurn
Follen, Michele
Cantor, Scott B.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Ctr Biomed Engn, Dept Biostat, Houston, TX 77030 USA
[2] British Columbia Canc Res Ctr, Dept Canc Imaging, Vancouver, BC V5Z 1L3, Canada
[3] Rice Univ, Dept Stat, Houston, TX 77005 USA
[4] Rice Univ, Dept Bioengn, Houston, TX 77005 USA
[5] Univ Texas, Hlth Sci Ctr, Dept Obstet Gynecol & Reprod Sci, Houston, TX 77030 USA
关键词
cervical intraepithelial neoplasia (CIN); sqaumous intraepithelial lesion (SIL); high-grade SIL (HG-SIL); in vivo cervical diagnosis; real-time diagnosis; optical spectroscopy; fluorescence spectroscopy; reflectance spectroscopy; multispectral imaging; point probe imaging; sensitivity and specificity;
D O I
10.1016/j.ygyno.2007.08.082
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. In this review, we evaluate the diagnostic efficacy of optical spectroscopy technologies (fluorescence and reflectance spectroscopy) for the in vivo diagnosis of cervical neoplasia using both point probe and multispectral imaging approaches. Methods. We searched electronic databases using the following terms: cervical cancer, cervical intraepithelial neoplasia, squamous intraepithelial lesion, and spectroscopy, fluorescence spectroscopy, or reflectance spectroscopy. We included studies that evaluated fluorescence and reflectance spectroscopy devices for in vivo diagnosis, compared those results with biopsy results, and reported on the sensitivity and specificity of the devices tested. Results. Twenty-six studies, including seven phase 11 trials and one randomized clinical trial, met our acceptability criteria. We found several important differences across the studies including device approach (multispectral versus point probe), study population, disease classification system, and disease threshold. This heterogeneity prevented formal combination of sensitivity and specificity results. Conclusion. Optical spectroscopy has similar performance to colposcopy and may help localize lesions and therefore be an effective adjunct to colposcopy. Reports on the diagnostic accuracy of these devices should use common thresholds for the construction of receiver operating characteristic curves to enable comparisons with standard technologies and facilitate their adoption. Optical spectroscopy has also been identified for possible use as ASCUS triage and primary screening, yet neither has been sufficiently evaluated to warrant a conclusion as to their suitability in this role. (C) 2007 Published by Elsevier Inc.
引用
收藏
页码:S138 / S146
页数:9
相关论文
共 57 条
  • [51] A real time optoelectronic device as an adjunct to the Pap smear for cervical screening: A multicenter evaluation
    Singer, A
    Coppleson, M
    Canfell, K
    Skladnev, V
    Mackellar, G
    Pisal, N
    Deery, A
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (06) : 804 - 811
  • [52] Optical spectroscopy for detection of neoplasia
    Sokolov, K
    Follen, M
    Richards-Kortum, R
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (05) : 651 - 658
  • [53] Reflectance spectroscopy with polarized light: is it sensitive to cellular and nuclear morphology
    Sokolov, Konstantin
    Drezek, Rebekah
    Gossage, Kirk
    Richards-Kortum, Rebecca
    [J]. OPTICS EXPRESS, 1999, 5 (13): : 302 - 317
  • [54] Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance
    Solomon, D
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 188 (06) : 1383 - 1392
  • [55] Autofluorescence spectroscopy for the diagnosis of cervical intraepithelial neoplasia
    Weingandt, H
    Stepp, H
    Baumgartner, R
    Diebold, J
    Xiang, W
    Hillemanns, P
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2002, 109 (08) : 947 - 951
  • [56] WRIGHT T, 1999, GYNECOL ONCOL, V72, P45
  • [57] 266 FDA